Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24077046 | 0.90 | NLRP3 (0.49) | NLRP3GPR139 | |
| SCHEMBL25749146 | 0.88 | NLRP3 (0.48) | NLRP3POLBALDH1A1GPR139CHRNA7 | |
| SCHEMBL24077192 | 0.87 | NLRP3 (0.59) | NLRP3GPR139CHRNA7GRIN1GRIN2B | |
| SCHEMBL24077359 | 0.87 | NLRP3 (0.59) | NLRP3GPR139CHRNA7GRIN1GRIN2B | |
| SCHEMBL24077057 | 0.84 | NLRP3 (0.51) | NLRP3POLBGPR139CHRNA7 | |
| SCHEMBL24077073 | 0.83 | NLRP3 (0.52) | NLRP3POLBCHRNA7 | |
| SCHEMBL24077048 | 0.83 | NLRP3 (0.50) | NLRP3POLBCHRNA7 | |
| SCHEMBL24077055 | 0.83 | NLRP3 (0.52) | NLRP3POLBCHRNA7 | |
| SCHEMBL24076326 | 0.82 | NLRP3 (0.58) | NLRP3POLBALDH1A1CHRNA7 | |
| SCHEMBL24077114 | 0.82 | NLRP3 (0.51) | NLRP3POLBGPR139CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | NLRP3 1/4885POLB 3231/4885ALDH1A1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.